201 related articles for article (PubMed ID: 32628022)
21. Pt(IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery.
Zheng YR; Suntharalingam K; Johnstone TC; Yoo H; Lin W; Brooks JG; Lippard SJ
J Am Chem Soc; 2014 Jun; 136(24):8790-8. PubMed ID: 24902769
[TBL] [Abstract][Full Text] [Related]
22. Are Pt(IV) Prodrugs That Release Combretastatin A4 True Multi-action Prodrugs?
Schmidt C; Babu T; Kostrhunova H; Timm A; Basu U; Ott I; Gandin V; Brabec V; Gibson D
J Med Chem; 2021 Aug; 64(15):11364-11378. PubMed ID: 34342437
[TBL] [Abstract][Full Text] [Related]
23. Synthesis, Structure, and Cytotoxicity of Oxaliplatin-Based Platinum(IV) Anticancer Prodrugs Bearing One Axial Fluoride.
Xu Z; Chan HM; Li C; Wang Z; Tse MK; Tong Z; Zhu G
Inorg Chem; 2018 Jul; 57(14):8227-8235. PubMed ID: 29943979
[TBL] [Abstract][Full Text] [Related]
24. Dual-targeting antitumor conjugates derived from platinum(IV) prodrugs and microtubule inhibitor CA-4 significantly exhibited potent ability to overcome cisplatin resistance.
Huang X; Wang M; Wang C; Hu W; You Q; Yang Y; Yu C; Liao Z; Gou S; Wang H
Bioorg Chem; 2019 Nov; 92():103236. PubMed ID: 31494328
[TBL] [Abstract][Full Text] [Related]
25. Platinum(IV)-nitroxyl complexes as possible candidates to circumvent cisplatin resistance in RT112 bladder cancer cells.
Cetraz M; Sen V; Schoch S; Streule K; Golubev V; Hartwig A; Köberle B
Arch Toxicol; 2017 Feb; 91(2):785-797. PubMed ID: 27307157
[TBL] [Abstract][Full Text] [Related]
26. Potent Chlorambucil-Platinum(IV) Prodrugs.
Aputen AD; Elias MG; Gilbert J; Sakoff JA; Gordon CP; Scott KF; Aldrich-Wright JR
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142383
[TBL] [Abstract][Full Text] [Related]
27. Effective platinum(IV) prodrugs conjugated with lonidamine as a functional group working on the mitochondria.
Chen H; Chen F; Hu W; Gou S
J Inorg Biochem; 2018 Mar; 180():119-128. PubMed ID: 29253663
[TBL] [Abstract][Full Text] [Related]
28. Synthesis, structural characterization, and antitumor properties of a novel class of large-ring platinum(II) chelate complexes incorporating the cis-1,4-diaminocyclohexane ligand in a unique locked boat conformation.
Hoeschele JD; Showalter HD; Kraker AJ; Elliott WL; Roberts BJ; Kampf JW
J Med Chem; 1994 Aug; 37(17):2630-6. PubMed ID: 8064793
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and cytotoxic activity of dextran carrying cis-dichloro(cyclohexane-trans-l-1,2-diamine)platinum(II) complex.
Ohya Y; Masunaga T; Baba T; Ouchi T
J Biomater Sci Polym Ed; 1996; 7(12):1085-96. PubMed ID: 8880440
[TBL] [Abstract][Full Text] [Related]
30. Model platinum nucleobase and nucleoside complexes and antitumor activity: X-ray crystal structure of [PtIV(trans-1R,2R-diaminocyclohexane)trans-(acetate)2(9-ethylguanine)Cl]NO3.H2O.
Ali MS; Khan SR; Ojima H; Guzman IY; Whitmire KH; Siddik ZH; Khokhar AR
J Inorg Biochem; 2005 Mar; 99(3):795-804. PubMed ID: 15708801
[TBL] [Abstract][Full Text] [Related]
31. Role of carrier ligand in platinum resistance in L1210 cells.
Gibbons GR; Page JD; Mauldin SK; Husain I; Chaney SG
Cancer Res; 1990 Oct; 50(20):6497-501. PubMed ID: 2208108
[TBL] [Abstract][Full Text] [Related]
32. Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers.
Pendyala L; Kidani Y; Perez R; Wilkes J; Bernacki RJ; Creaven PJ
Cancer Lett; 1995 Nov; 97(2):177-84. PubMed ID: 7497460
[TBL] [Abstract][Full Text] [Related]
33. A CK2-targeted Pt(IV) prodrug to disrupt DNA damage response.
Chen F; Huang X; Wu M; Gou S; Hu W
Cancer Lett; 2017 Jan; 385():168-178. PubMed ID: 27793693
[TBL] [Abstract][Full Text] [Related]
34. Synthesis, characterization, and antitumor activity of new platinum(IV) trans-carboxylate complexes: crystal structure of [Pt(cis-1,4-DACH)trans-(acetate)2Cl2].
Shamsuddin S; Santillan CC; Stark JL; Whitmire KH; Siddik ZH; Khokhar AR
J Inorg Biochem; 1998 Aug; 71(1-2):29-35. PubMed ID: 9755489
[TBL] [Abstract][Full Text] [Related]
35. Monochalcoplatin: An Actively Transported, Quickly Reducible, and Highly Potent Pt
Ma L; Wang N; Ma R; Li C; Xu Z; Tse MK; Zhu G
Angew Chem Int Ed Engl; 2018 Jul; 57(29):9098-9102. PubMed ID: 29806087
[TBL] [Abstract][Full Text] [Related]
36. Promising Anticancer Prodrugs Based on Pt(IV) Complexes with Bis-organosilane Ligands in Axial Positions.
Navas F; Chocarro-Calvo A; Iglesias-Hernández P; Fernández-García P; Morales V; García-Martínez JM; Sanz R; De la Vieja A; García-Jiménez C; García-Muñoz RA
J Med Chem; 2024 Apr; 67(8):6410-6424. PubMed ID: 38592014
[TBL] [Abstract][Full Text] [Related]
37. Impact of Mitochondrion-Targeting Group on the Reactivity and Cytostatic Pathway of Platinum(IV) Complexes.
Jin S; Hao Y; Zhu Z; Muhammad N; Zhang Z; Wang K; Guo Y; Guo Z; Wang X
Inorg Chem; 2018 Sep; 57(17):11135-11145. PubMed ID: 30117731
[TBL] [Abstract][Full Text] [Related]
38. Different apoptotic effects of [Pt(O,O'-acac)(γ-acac)(DMS)] and cisplatin on normal and cancerous human epithelial breast cells in primary culture.
Vetrugno C; Muscella A; Fanizzi FP; Cossa LG; Migoni D; De Pascali SA; Marsigliante S
Br J Pharmacol; 2014 Nov; 171(22):5139-53. PubMed ID: 24990093
[TBL] [Abstract][Full Text] [Related]
39. Synthesis, antiproliferative activity in cancer cells and DNA interaction studies of [Pt(cis-1,3-diaminocycloalkane)Cl
Hoeschele JD; Kasparkova J; Kostrhunova H; Novakova O; Pracharova J; Pineau P; Brabec V
J Biol Inorg Chem; 2020 Sep; 25(6):913-924. PubMed ID: 32851480
[TBL] [Abstract][Full Text] [Related]
40. Influence of Ring Modifications on Nucleolar Stress Caused by Oxaliplatin-Like Compounds.
McDevitt CE; Guerrero AS; Smith HM; DeRose VJ
Chembiochem; 2022 Jul; 23(14):e202200130. PubMed ID: 35475312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
